[Therapy strategies for advanced renal cell carcinoma].
The therapeutic regimen for metastatic renal cell cancer has changed substantially in the last years. Formerly, metastatic disease was regarded as being inoperable and had a disastrous prognosis. Nowadays, radical nephrectomy is the accepted urologic-oncologic standard therapy in metastatic primaries, if technically feasible. A complete resection of metastases may be curative, or can achieve a substantial palliative benefit. A better understanding of prognostic parameters helps in the selection of patients with a chance of benefiting from systemic immunochemotherapy. For patients with rapidly progressing tumors or sarcomatoid dedifferentiation, new effective chemotherapy regimens are available. New angiogenesis inhibitors such as sutent, avastin or sorafenib can potentially be effectively used in future therapeutic regimens.
Staehler
M
M
Urologische Universitätsklinik, Klinikum Grosshadern der Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich. michael.staehler@med.uni-muenchen.de
Haseke
N
N
Schöppler
G
G
Stadler
T
T
Adam
C
C
Stief
C G
CG
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D005858:Germany; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007680:Kidney Neoplasms / Q000628:therapy*; D009392:Nephrectomy / Q000379:methods*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents